H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Spruce Biosciences (SPRB) to $200 from $220 and keeps a Buy rating on the shares. The firm says the timing for completion of the tralesinidase alfa enzyme replacement therapy filing is now anticipated in Q4 versus Q1 previously.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences provides update on Type B tralesinidase meetings with FDA
- 3 ‘Strong Buy’ Stocks to Buy Now, 2/6/2026, According to Top Analysts
- Spruce Biosciences: TA-ERT’s Promising Long-Term Data and Priority Review Voucher Upside Underpin Reiterated Buy and $220 Target
- Spruce Biosciences Highlights Promising Long-Term Tralesinidase Data
- Harbour BioMet acquires common stock in Spruce Biosciences